Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Sep 28, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Operating Expenses (2012 - 2026)

Updated

Inhibitor Therapeutics (INTI) posted Operating Expenses of $618,597 for Q2 2026, down 11.1% from $695,773 a year earlier and down 11.1% from the prior quarter.

Analysis

Inhibitor Therapeutics (INTI) Operating Expenses (2012 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Inhibitor Therapeutics was $3.37 million, down 8.1% year-over-year; for FY2025, it was $3.43 million, down 6.3% from FY2024.

  • Annual Operating Expenses shows a five-year compound annual growth rate of 26.5% (FY2020 to FY2025).
  • In prior years, Inhibitor Therapeutics' Operating Expenses was $3.66 million in FY2024 (+7.4%), $3.4 million in FY2023 (+417.5%), $657,926 in FY2022 (+102.2%) and $325,395 in FY2021 (-69.3%).
  • The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q2 2024.
  • On a year-over-year basis, Operating Expenses increased in four of the last eight quarters, with growth averaging 0.2%.
  • The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2023, with growth of 985.2%; the weakest was Q3 2021, with a decline of 78.1%.
  • According to Business Quant data, Operating Expenses for the three prior quarters was $695,632 (Q1 2026), $1.32 million (Q4 2025) and $741,215 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 10.12 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 10.56 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 12.80 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -6.09 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -9.70 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 6.54 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 18.20 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 6.68 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 2.09 Bn
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn - 618,597.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 618,597.00
Mar 31, 2026 695,632.00
Dec 31, 2025 1.32 Mn
Sep 30, 2025 741,215.00
Jun 30, 2025 695,773.00
Mar 31, 2025 674,551.00
Dec 31, 2024 1.48 Mn
Sep 30, 2024 813,196.00
Jun 30, 2024 585,147.00
Mar 31, 2024 774,817.00
Dec 31, 2023 1.27 Mn
Sep 30, 2023 759,528.00
Jun 30, 2023 742,461.00
Mar 31, 2023 629,724.00
Dec 31, 2022 423,635.00
Sep 30, 2022 69,987.00
Jun 30, 2022 70,804.00
Mar 31, 2022 93,500.00
Dec 31, 2021 28,759.00
Sep 30, 2021 66,248.00
API Access

Inhibitor Therapeutics Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY